Was the Esperion (ESPR) share grant to Robert E. Hoffman an open-market purchase?

No, the transaction was reported with code A, described as a grant, award, or other acquisition. The shares were awarded at a reported price of $0.00 per share, indicating equity compensation rather than an open-market purchase.

Esperion (NASDAQ: ESPR) director receives 79,873-share stock grant

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Hoffman Robert E. reported acquisition or exercise transactions in this Form 4 filing.

Esperion Therapeutics director Robert E. Hoffman received an equity grant of 79,873 shares of Common Stock, reported at a price of $0.00 per share as a compensation award. Following this grant, he directly holds 85,153 shares of Esperion common stock.

The award vests in full on the earlier of May 28, 2027 or Esperion’s next annual meeting of stockholders following May 28, 2026, linking vesting to either time-based service or the company’s stockholder meeting schedule.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Hoffman Robert E.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	79,873	$0.00	--

Holdings After Transaction: Common Stock — 85,153 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares granted: 79,873 shares Post-transaction holdings: 85,153 shares Grant price per share: $0.00 per share +1 more

4 metrics

Shares granted 79,873 shares Common Stock grant to director on May 28, 2026

Post-transaction holdings 85,153 shares Director’s direct ownership after grant

Grant price per share $0.00 per share Reported value for awarded shares

Vesting date trigger May 28, 2027 Full vesting if earlier than stockholders’ meeting

Key Terms

Grant, award, or other acquisition, vest in full, annual meeting of stockholders

3 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vest in full financial

"The awards vest in full on the earlier of May 28, 2027"

annual meeting of stockholders regulatory

"the Issuer's next annual meeting of stockholders following May 28, 2026"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/01/2026 - 04:23 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hoffman Robert E.

(Last)

(First)

(Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR

MICHIGAN

48108

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/28/2026		A		79,873⁽¹⁾	A	$0	85,153	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.

Remarks:

	/s/ Sheldon L. Koenig, by power of attorney	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Esperion Therapeutics (ESPR) disclose in this Form 4 filing?

Esperion reported that director Robert E. Hoffman received a grant of 79,873 shares of Common Stock. The award is a compensation-related acquisition and increases his direct holdings to 85,153 shares after the transaction.

How many Esperion (ESPR) shares were granted to Robert E. Hoffman?

Robert E. Hoffman was granted 79,873 shares of Esperion Common Stock. The transaction was coded as a grant, award, or other acquisition, reflecting equity-based compensation rather than an open-market purchase of shares.

When do Robert E. Hoffman’s new Esperion (ESPR) shares vest?

The granted shares vest in full on the earlier of May 28, 2027 or Esperion’s next annual meeting of stockholders following May 28, 2026. This means vesting is tied to either a time-based milestone or the company’s stockholder meeting schedule.

What are Robert E. Hoffman’s Esperion (ESPR) holdings after this Form 4 transaction?

After the equity award, Robert E. Hoffman directly owns 85,153 shares of Esperion Common Stock. This total reflects his position immediately following the reported grant of 79,873 shares in the Form 4 filing.